CEO Pascal Soriot spent a decade building AstraZeneca by saying no to bad deals — and now the market is punishing him for a deal he may never do.
Shares have slid more than 19% in under a month, first on a failed heart drug trial, then on reports of merger talks with Bristol Myers.
Reuters later quoted a senior source denying any ongoing discussions. Even so, the stock remains under pressure, suggesting investors are still pricing in a risk that may never materialize. That's the opportunity.
When Pfizer came knocking with a $120B takeover bid in 2014, Soriot walked away. He then grew revenue to nearly $60B by backing internal R&D and targeted acquisitions.
That playbook is still running. In H1 2026, total revenue rose 6% at constant exchange rates, driven by double-digit growth in oncology and rare disease.
The company reconfirmed full-year guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth.
AstraZeneca's oncology segment generates 46% of total sales, and the US accounts for 42% of revenue. The balance sheet is clean, with net interest costs covered 11 times by operating profits in the first half.
More than 20 high-value clinical readouts are expected over the next 18 months, and 30 approvals have already landed in major markets since Q4 2025.
The reported rationale is US scale. Bristol Myers runs a highly profitable, US-centric business that would hand AstraZeneca a major commercial footprint in a single move.
But the combined company would grow at roughly 1% annually through 2032, compared with AstraZeneca's standalone estimate of ~5%.
Bristol Myers' two biggest drugs, Opdivo and Eliquis, face loss of exclusivity starting in 2028. AstraZeneca's most significant patent expiries don't arrive until 2031 to 2033.
The antitrust exposure is severe too: both companies sell checkpoint inhibitors targeting non-small cell lung cancer, and a combined oncology portfolio would almost certainly draw regulatory scrutiny.
A study cited by analysts found that pharma mergers with overlapping therapeutic areas led to 53% more discontinued drug programs than comparable non-merging companies.
AstraZeneca's pipeline is widely regarded as the stronger of the two, and absorbing Bristol Myers could slow it down.
At less than 15 times forward earnings, AstraZeneca trades well below its 10-year average of 18 times. The Times pegs the current price-to-earnings ratio at 16.8, still a discount to history for a company posting this growth profile.
Rivals Eli Lilly and Johnson & Johnson sit at roughly $1T and $600B in market cap, respectively, while AstraZeneca sits at ~$250B.
"If the merger rumours prove to be true, this would represent the pharmaceutical industry's equivalent of the FIFA privatisation moment."
Markus Manns, Union Investment
Soriot has spent more than a decade proving he doesn't need blockbuster acquisitions to grow AstraZeneca. The recent $600M upfront licensing agreement for Dizal Pharmaceutical's lung cancer drug Zegfrovy fits the same disciplined approach that has defined his tenure. Yet the market is pricing the company as though that strategy has already changed.
Ford Targets Mass Market With New Affordable Fathom EV Pickup
